TAC

Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy

Retrieved on: 
Tuesday, June 20, 2023
Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Physiology, Rat, MMF, Hypercalciuria, Magnesium, European Renal Association, CSA, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Lupus, Kidney, Calcium, Nephritis, ERA, Proteinuria, TAC, Patient, VCS, Annual general meeting, CNI, UPCR, Safety, Pharmaceutical industry, LN, Aurinia

The findings presented at ERA this week show that voclosporin achieved a 50% proteinuria reduction at 28 days, compared to 57 days in the control arm (p90% renal reabsorption was observed for both CSA and TAC in this study, whereas the renal handling of VCS suggested a significant component of tubular secretion.

Key Points: 
  • The findings presented at ERA this week show that voclosporin achieved a 50% proteinuria reduction at 28 days, compared to 57 days in the control arm (p
  • “Additionally, in two pre-clinical animal models, voclosporin showed a higher rate of renal secretion, lower overall kidney exposure, and no associated hypercalciuria or hypomagnesemia, compared to the legacy, first-generation CNIs.
  • Higher drug exposure and >90% renal reabsorption was observed for both CSA and TAC in this study, whereas the renal handling of VCS suggested a significant component of tubular secretion.
  • The data showed that the tubulotoxicity observed with TAC is not apparent with VCS treatment at clinically relevant doses.3

Dr. Terry Nisbet Joins Newly Formed Technical Advisory Committee

Retrieved on: 
Thursday, June 8, 2023
Data Management, Semiconductor, Technology, Nanotechnology, Other Technology, Telecommunications, Hardware, Gallium nitride, UMS, Institute of Engineering and Technology, Defense, Marketing, Prix, Automotive industry, Doctor of Philosophy, Bachelor of Science, Electronic, Retirement, TAC, Thales Group, United Kingdom, Commercial, Gallium arsenide, TIDEL Park Coimbatore, RF, Communications satellite, Management, Engineering, Ferranti, Airbus

MACOM Technology Solutions Inc. (“MACOM” or the “Company”), a leading supplier of semiconductor products, today announced that Dr. Terry Nisbet will join MACOM’s newly established Technical Advisory Committee (“TAC”).

Key Points: 
  • MACOM Technology Solutions Inc. (“MACOM” or the “Company”), a leading supplier of semiconductor products, today announced that Dr. Terry Nisbet will join MACOM’s newly established Technical Advisory Committee (“TAC”).
  • MACOM’s TAC members will act in an independent advisory capacity to MACOM, supporting growth strategies, technical roadmaps and expanding the Company’s network.
  • “I am pleased to welcome Terry to our TAC,” said Stephen G. Daly, MACOM’s President and Chief Executive Officer.
  • Dr. Nisbet holds a BSc and PhD in the fields of Electrical, Electronic and Microwave Engineering from Herlot-Watt University in Edinburgh.

Triumvira Immunologics Highlights Positive Phase 1 Clinical Data on TAC01-HER2 in Solid Tumors at ASCO 2023 Annual Meeting

Retrieved on: 
Wednesday, May 31, 2023
Interim, American Society of Clinical Oncology, Therapy, CRS, DL, DCR, DLT, DL 2, Oncology, Harvard Medical School, Presentation Public School, ASCO, TAC, MD, Patient, GEJ, Annual general meeting, Toxic epidermal necrolysis, ICU, ORR, News, Safety, Dana–Farber Cancer Institute, Pharmaceutical industry, Medicine

"We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.

Key Points: 
  • "We are encouraged by the promising results from the TACTIC-2 trial, which demonstrate the safety and compelling clinical activity of autologous TAC01-HER2 in refractory solid tumors," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics.
  • These findings warrant further investigation and hold promise for addressing the therapeutic needs of patients with HER2-positive gastric and esophageal cancers."
  • Interim results from the Phase I TACTIC-02 study suggest a highly favorable safety profile for TAC-01 HER2 treatment with the potential of being an outpatient procedure.
  • A copy of the presentations will be available after the closure of the meeting, under the Presentations & Publications tab of the News & Resources section of the Company's website .

2 Day Seminar: Gain an Understanding of Today's U.S. Electric Power Industry - Focus on Renewable Energy, ISO Markets, and Power Transactions (Hilton Head Island, United States - July 18-19, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, May 22, 2023
Utilities, Energy, OASIS, Term sheet, DER, Magic, Marketing, ICE, ISO, Electricity, Risk management, Strategic planning, Wind, FERC, Var, Renewable energy, TAC, Non-bank financial institution, Carnegie Mellon University, NERC, Risk, Optical disc image, Monolithic kernel, Natural gas, Professional, LMP, Appendix, Utility, FTR Moto, BESS, Electric power, Cryptocurrency, Transformer, Public utility, Entertainment, Financial adviser, Auction, Wholesaling, Recycling, Oil, Airline, Security (finance), Bank, Distribution (marketing), Warehouse, Online shopping, Sintering, Bookkeeping

Fundamentals of utility cost-of-service regulation, open access markets

Key Points: 
  • Fundamentals of utility cost-of-service regulation, open access markets
    Why utilities sometimes resist renewable energy, distributed energy resource (DER"), rooftop solar, and conservation projects.
  • Federal vs state regulatory conflicts, and why restructuring today's power industry and the building new power lines is such a complicated task.
  • The structure and functions of ISOs, RTOs, the Western Energy Imbalance Market ("WEIM"), and the new Southeast Energy Exchange Market ("SEEM").
  • John Adamiak is President and Founder of PGS Energy Training and an expert in energy derivatives and electric power markets.

Keros Therapeutics Presents Preclinical and Clinical Data from its KER-012 Program at the American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
GDF11, Mouse, Endothelial dysfunction, Heart failure, TGF, Heart, PAH, Serum, ATS, Matrix metalloproteinase inhibitor, Cardiac fibrosis, SMAD, Pharmacokinetics, Woman, IL-6, Research, Part, Inflammation, Biomarker, American Thoracic Society, SMAD2, Administration, TAC, MARCO, Asilomar International Conference on Climate Intervention Technologies, Patient, Vascular remodelling in the embryo, Orthostatic hypertension, Therapy, Hypoxia, Conference, Endothelium, Safety, KROS, Pharmaceutical industry, Medical device, Extractive metallurgy, Vaccine, Trapping, Fibrosis

“We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.

Key Points: 
  • “We are pleased to present clinical and preclinical data from our KER-012 program at the ATS conference this year.
  • The preclinical presentations demonstrate observed ligand selectivity of KER-012 and changes in inflammation and fibrosis in models of PAH and cardiovascular diseases.
  • Keros reported preliminary topline data from the Part 1 single ascending dose portion of the trial in May 2022, and additional preliminary clinical data from the Part 2 multiple ascending dose portion of the trial in September 2022.
  • HPAECs and HPASMCs were treated with activin A, GDF11, or bone morphogenetic protein 9 (“BMP9”) in the presence of KER-012.

CRITEO REPORTS FIRST QUARTER 2023 RESULTS

Retrieved on: 
Wednesday, May 3, 2023
Acceleration, Treasury, Rite Aid, Media, Retail media, ASOS, Forecasting, EBITDA, TAC, Acquisition, Annual general meeting, Investment, Appendix, Depreciation, Contribution, EPS, Management, Sales, Video game, Holding company, Bookkeeping, Cryptocurrency, Retail, Security (finance), Bank, Insurance, Criteo, Travel, Adjustment

NEW YORK, May 3, 2023 /PRNewswire/ -- Criteo S.A. (NASDAQ: CRTO) ("Criteo" or the "Company"), the commerce media company, today announced financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Revenue for Q1 2023 was $445 million, gross profit was $182 million and Contribution ex-TAC was $221 million.
  • In the course of the first quarter 2023, we incurred $9 million in restructuring related and transformation costs.
  • The above guidance assumes that no additional acquisitions are completed during the second quarter of 2023 or the fiscal year ended December 31, 2023.
  • Because of these and other limitations, you should consider these measures alongside our U.S. GAAP financial results, including revenue and net income.

Perion’s Momentum Continues, Delivering 16% Revenue Growth and 54% Increase in Net Income

Retrieved on: 
Wednesday, May 3, 2023
Technology, Finance, Marketing, Other Technology, Advertising, Communications, Professional Services, Audio, Video, Digital Marketing, Growth, IHub, CTV, TAC, RPM, EBITDA, Adjustment, GAAP, Perion Network, Video game, Cryptocurrency

Revenue: Revenue increased by 16% to $145.2 million in the first quarter of 2023 from $125.3 million in the first quarter of 2022.

Key Points: 
  • Revenue: Revenue increased by 16% to $145.2 million in the first quarter of 2023 from $125.3 million in the first quarter of 2022.
  • Growth was primarily due to a 26% increase in video revenue, 12% increase in CTV revenue, 93% increase in SORT® customer spending and a 60% year-over-year increase in Retail media revenue.
  • Net Income: On a GAAP basis, net income increased by 54% to $23.8 million in the first quarter of 2023 from $15.5 million in the first quarter of 2022.
  • Non-GAAP net income was $29.9 million, or 21% of revenue, in the first quarter of 2023, compared with $20.7 million, or 17% of revenue, in the first quarter of 2022.

TransAlta Corporation Announces Results of the Annual and Special Meeting of Shareholders and Election of all Directors

Retrieved on: 
Saturday, April 29, 2023
TSX, AB, TAC, TransAlta, TA, Meeting, NYSE, Proxy, Special, Security (finance)

CALGARY, AB, April 28, 2023 /PRNewswire/ - TransAlta Corporation (TSX: TA) (NYSE: TAC) ("TransAlta" or the "Company") held its Annual and Special Meeting of Shareholders ("the Meeting") on April 28, 2023.

Key Points: 
  • CALGARY, AB, April 28, 2023 /PRNewswire/ - TransAlta Corporation (TSX: TA) (NYSE: TAC) ("TransAlta" or the "Company") held its Annual and Special Meeting of Shareholders ("the Meeting") on April 28, 2023.
  • The total number of common shares represented by shareholders at the Meeting and by proxy was 151,051,401, representing 56.49 per cent of the Company's outstanding common shares.
  • The following resolutions were considered by shareholders:
    The thirteen director nominees proposed by management were elected.
  • The votes by ballot were received as follows:

TransAlta Declares Dividends

Retrieved on: 
Friday, April 28, 2023
TSX, AB, TAC, TransAlta, TA, NYSE, Holding company, Management

CALGARY, AB, April 27, 2023 /PRNewswire/ - The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC) declared a quarterly dividend of $0.055 per common share payable on July 1, 2023 to shareholders of record at the close of business on June 1, 2023.

Key Points: 
  • CALGARY, AB, April 27, 2023 /PRNewswire/ - The Board of Directors of TransAlta Corporation (TSX: TA) (NYSE: TAC) declared a quarterly dividend of $0.055 per common share payable on July 1, 2023 to shareholders of record at the close of business on June 1, 2023.
  • The Board of Directors also declared the following quarterly dividend on its Cumulative Redeemable Rate Reset First Preferred Shares for the period starting from and including March 31, 2023 up to but excluding June 30, 2023:

Triumvira Immunologics Presents Promising Data on TAC T Cells for the Treatment of HER2-overexpressing Solid Tumors at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, April 18, 2023
Abstract (summary), AACR, Therapy, HER2, Cancer, Toxicity, Eftilagimod alpha, TAC, CD8, Patient, Mouse, Neoplasm, CD4, T, White, Safety, Pharmaceutical industry, Medical imaging, Vaccine

The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Key Points: 
  • The presentations will include updated clinical data from the ongoing TACTIC-2 trial of TAC01-HER2 ( NCT04727151 ) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.
  • TAC01-HER2 obtained a disease control rate of 67% in heavily pretreated patients with solid tumors in patients who failed all standard of care therapies.
  • In a 5-day in vitro potency assay, patient-derived products showed effective tumor cell killing response similar to healthy-donor derived TAC T cells.
  • HER2-TAC γδ (gamma/delta) T cells selectively react to and kill HER2-expressing tumor cells in co-culture at low effector-to-target ratios, indicating strong functionality.